Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

First-in-human trial of ETX–636 to begin in Q2 2025 in patients with tumors harboring an activating PI3Kα mutation, including breast cancer ...